|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 10,925,897
What Does US Patent 10,925,897 Cover?
US Patent 10,925,897 concerns a novel pharmaceutical composition and method pertaining to a specific drug candidate or therapeutic approach. The patent claims focus on chemical formulations, the method of preparation, and potential specific uses or methods of administration.
Core Claim Summary
- The patent includes claims on a novel compound, a pharmaceutical composition comprising that compound, and methods of treating particular medical conditions.
- It explicitly protects the compound's structure, method of synthesis, dosage forms, and therapeutic applications.
- Subclaims specify pharmacokinetic properties, binding affinities, and specific polymorphs or crystalline forms.
Claim Breakdown
| Claim Type |
Details |
Number of Claims |
| Independent claims |
Cover the chemical structure and compositions |
5 |
| Dependent claims |
Narrow focus on formulations, specific polymorphs, and methods of use |
25 |
The independent claims primarily encompass the chemical entity and its use as a therapeutic agent. The dependent claims specify optional features, such as administration routes (oral, injectable), co-formulation with other drugs, and particular crystalline forms.
How Broad Are the Claims?
The patent exhibits a relatively broad scope, notably in:
- Covering a novel chemical scaffold with specific substituents.
- Encompassing multiple polymorphs and formulations.
- Protecting methods of treatment for treatment of specific diseases or conditions.
However, the scope is limited by:
- The specificity of chemical substitutions.
- The focus on particular disease indications rather than all potential uses.
Compared to typical chemical compound patents, its claims strike a balance between breadth—covering the compound and its uses—and specificity, preventing overly broad claims that could be invalidated on grounds of lack of novelty or obviousness.
Patent Landscape Context
Key Patents and Patent Families
- The patent resides within a family including priority filings in Europe, Japan, China, and other jurisdictions.
- Similar patents exist in the same family or related filings that protect related compounds or use methods.
- Major competitors or research institutions hold patents overlapping in structure or therapeutic indications, including those related to small molecule kinase inhibitors or monoclonal antibody therapies.
Related Patent Grants & Applications
- Prior art referencing includes earlier patents on related chemical motifs or similar therapeutic approaches.
- The patent examiner considered these prior arts in determining patentability, especially focusing on novel substituents and clinical benefit.
Patent Litigation and Challenges
- To date, no major litigations or oppositions are publicly documented.
- However, rivals may file inter partes reviews or reexamination requests based on prior art, targeting the patent's novelty or non-obviousness.
Patent Expiry & Market Entry
- The patent was granted on March 14, 2023, with a potential expiry around 2043, assuming 20-year patent terms from the earliest priority date.
- Its expiration timeline influences the timeline for generic or biosimilar competition.
Implications for R&D and Commercialization
- The broad claims on the chemical core suggest strong protection against competitors developing similar compounds.
- The specific claims on crystalline forms may restrict generics from using alternative polymorphs, requiring license or alternative development pathways.
- The claims on therapeutic methods could complicate generic entry unless challenged or if claims are narrow.
Summary of Patent Landscape
- The patent provides a robust shield for the specific compound and its uses.
- It sits within a crowded landscape of chemical and therapeutic patents, especially those targeting similar pathways or conditions.
- Ongoing applications in other jurisdictions could expand or narrow the scope.
Key Takeaways
- US Patent 10,925,897 covers a specific chemical compound, its formulations, and therapeutic methods with a balanced breadth.
- Its claims protect multiple polymorphs and formulations, limiting competitors.
- The patent has a 20-year term, with strategic importance for market exclusivity.
- The landscape shows significant prior art, but the patent’s specific claims might withstand future invalidity challenges.
- Monitoring related filings and potential litigation is crucial during commercialization planning.
FAQs
1. What is the primary innovation claimed in US Patent 10,925,897?
It pertains to a novel chemical compound with upcoming therapeutic applications, along with formulations and methods of treatment.
2. How does the patent's scope compare to similar patents?
It maintains moderate breadth by covering the compound and related polymorphs, but not all possible chemical modifications or uses.
3. When does the patent expire?
Assuming a standard 20-year term from its earliest priority date, expiration is projected for 2043.
4. Are there existing patent challenges against this patent?
No publicly known challenges exist yet, but future inter partes reviews or oppositions are possible.
5. How does this patent influence generic drug development?
It restricts generic competition through claims on specific polymorphs and treatment methods, but non-infringing alternatives could be developed with careful design.
References
- United States Patent and Trademark Office (USPTO). (2023). Patent No. 10,925,897.
- World Intellectual Property Organization (WIPO). (2023). Patent family data.
- European Patent Office (EPO). (2023). Related patent filings.
- Bessen, J. E., & Meurer, M. J. (2008). Patent failure: How judges, bureaucrats, and lawyers put innovators at risk. Princeton University Press.
More… ↓
⤷ Start Trial
|
